SMS Lifesciences India Limited (SMSLIFE.BO)
INR 1518.7
(-1.79%)
INR 1518.7
(-1.79%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 992.31 Million INR | 0.02% |
| 2022 | 992.12 Million INR | 26.21% |
| 2021 | 786.11 Million INR | 40.0% |
| 2020 | 561.49 Million INR | -10.07% |
| 2019 | 624.37 Million INR | 39.0% |
| 2018 | 449.18 Million INR | 66.88% |
| 2017 | 269.17 Million INR | 3.64% |
| 2016 | 259.72 Million INR | -26.11% |
| 2015 | 351.47 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 44.12 Million INR | -95.55% |
| 2023 Q3 | 19.56 Million INR | -97.92% |
| 2023 FY | 992.31 Million INR | 0.02% |
| 2023 Q4 | 992.31 Million INR | 4972.4% |
| 2023 Q2 | 941.61 Million INR | 2033.82% |
| 2022 Q1 | 43.92 Million INR | -94.41% |
| 2022 Q3 | 41.12 Million INR | -95.46% |
| 2022 Q2 | 904.95 Million INR | 1960.47% |
| 2022 FY | 992.12 Million INR | 26.21% |
| 2022 Q4 | 992.12 Million INR | 2312.33% |
| 2021 Q4 | 786.11 Million INR | 1620.95% |
| 2021 Q2 | 622.7 Million INR | 462.83% |
| 2021 Q1 | 110.63 Million INR | -80.3% |
| 2021 FY | 786.11 Million INR | 40.0% |
| 2021 Q3 | 45.67 Million INR | -92.66% |
| 2020 Q3 | 60.6 Million INR | -91.47% |
| 2020 Q1 | 75.93 Million INR | -87.84% |
| 2020 FY | 561.49 Million INR | -10.07% |
| 2020 Q4 | 561.49 Million INR | 826.45% |
| 2020 Q2 | 710.85 Million INR | 836.1% |
| 2019 Q3 | 50.35 Million INR | -88.64% |
| 2019 Q2 | 443.27 Million INR | 1597.67% |
| 2019 FY | 624.37 Million INR | 39.0% |
| 2019 Q1 | 26.11 Million INR | -94.19% |
| 2019 Q4 | 624.37 Million INR | 1139.87% |
| 2018 Q3 | 6.6 Million INR | -97.39% |
| 2018 Q2 | 252.73 Million INR | 2697.26% |
| 2018 Q1 | 9.03 Million INR | -96.64% |
| 2018 FY | 449.18 Million INR | 66.88% |
| 2018 Q4 | 449.18 Million INR | 6700.71% |
| 2017 FY | 269.17 Million INR | 3.64% |
| 2017 Q1 | 29.08 Million INR | -88.8% |
| 2017 Q4 | 269.17 Million INR | 0.0% |
| 2017 Q2 | 181.2 Million INR | 522.99% |
| 2016 Q4 | 259.72 Million INR | 0.0% |
| 2016 Q1 | 16 Thousand INR | 0.0% |
| 2016 FY | 259.72 Million INR | -26.11% |
| 2015 FY | 351.47 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 1.35 Billion INR | 26.755% |
| Biocon Limited | 140.18 Billion INR | 99.292% |
| Blue Jet Healthcare Limited | -830.93 Million INR | 219.422% |
| Concord Biotech Limited | -372.86 Million INR | 366.13% |
| Dishman Carbogen Amcis Limited | 18.99 Billion INR | 94.775% |
| FERMENTA BIOTECH LIMITED | 1.1 Billion INR | 10.151% |
| GENOMIC VALLEY BIOTECH LIMITED | -60.73 Thousand INR | 1633967.356% |
| Lyka Labs Limited | 527.01 Million INR | -88.29% |
| Panacea Biotec Limited | -1.18 Billion INR | 183.747% |
| SAMSRITA LABS LIMITED | 21.98 Million INR | -4412.713% |
| Servoteach Industries Limited | 5016.00 INR | -19782854.545% |
| Supriya Lifescience Limited | -694.68 Million INR | 242.845% |
| Syngene International Limited | -83 Million INR | 1295.558% |
| TAKE Solutions Limited | 361.37 Million INR | -174.598% |
| Titan Biotech Limited | 54.62 Million INR | -1716.492% |
| Transgene Biotek Limited | 139.93 Million INR | -609.134% |
| Vanta Bioscience Limited | 607.93 Million INR | -63.228% |